Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	1.78B
Revenue (ttm)	208.70M
Net Income (ttm)	-853.81M
Shares Out	2.21B
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,913,219
Open	0.840
Previous Close	0.839
Day's Range	0.789 - 0.869
52-Week Range	0.720 - 2.545
Beta	1.42
Analysts	Sell
Price Target	1.90 (+135.85%)
Earnings Date	May 9, 2024

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,218
• Stock Exchange: NYSE
• Ticker Symbol: DNA

Financial Performance

In 2023, DNA's revenue was $251.46 million, a decrease of -47.36% compared to the previous year's $477.71 million. Losses were -$892.87 million, -57.58% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $1.9, which is an increase of 135.85% from the latest price.

Price Target

$1.9

(135.85% upside)

Analyst Consensus: Sell